SCHEMBL425487

SCHEMBL425487

CNS(=O)(=O)c1ccc(F)c(F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.58
TDP1 Q9NUW8 1/20 0.58
CA12 O43570 2/20 0.55
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA3 P07451 2/20 0.55
CA4 P22748 2/20 0.55
CA6 P23280 2/20 0.55
CA5A P35218 2/20 0.55
CA7 P43166 2/20 0.55
CA9 Q16790 2/20 0.55
CA13 Q8N1Q1 2/20 0.55
CA14 Q9ULX7 2/20 0.55
CA5B Q9Y2D0 2/20 0.55
LMNA P02545 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
GAA P10253 1/20 0.52
KIF11 P52732 1/20 0.51
TAS2R14 Q9NYV8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16519527 0.84 LMNA (0.65) KMT2ACA12CA1CA2CA3
SCHEMBL10153819 0.84 TSHR (0.61) KMT2ACA12CA1CA2CA3
SCHEMBL1804387 0.82 CA1 (0.50) KMT2ATDP1CA12CA1CA2
SCHEMBL29167246 0.82 CA12 (0.60) KMT2ACA12CA1CA2CA3
SCHEMBL20779633 0.82 CA1 (0.50) KMT2ATDP1CA12CA1CA2
SCHEMBL3017872 0.82 LMNA (0.49) KMT2ATDP1CA12CA1CA2
SCHEMBL31347291 0.82 CA1 (0.61) KMT2ATDP1CA12CA1CA2
SCHEMBL22612213 0.82 CA1 (0.61) KMT2ATDP1CA12CA1CA2
SCHEMBL14378094 0.80 KMT2A (0.54) KMT2ATDP1LMNASMN1; SMN2HTT
SCHEMBL22747086 0.80 CA12 (0.47) KMT2ATDP1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4399216-A1 IMMUNOMODULATING AZALIDES Zoetis Services LLC (US) 2024-07-17 EP disclosed
WO-2023038852-A1 IMMUNOMODULATING AZALIDES ZOETIS SERVICES LLC (US) 2023-03-16 WO disclosed
EP-2239253-B1 NOVEL PHENYLPYRROLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2013-06-19 EP disclosed
US-8415359-B2 Phenylpyrrole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-04-09 US disclosed
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
US-20120022075-A1 NOVEL PHENYLPYRROLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-26 US disclosed
EP-2397479-A1 HETERO RING DERIVATIVE Astellas Pharma Inc. (JP) 2011-12-21 EP disclosed
US-8017610-B2 Phenylpyrrole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-09-13 US disclosed
US-20110003787-A1 NOVEL PHENYLPYRROLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-01-06 US disclosed
EP-2239253-A1 NOVEL PHENYLPYRROLE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2010-10-13 EP disclosed
WO-2010092962-A1 HETERO RING DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003787-A1 NOVEL PHENYLPYRROLE DERIVATIVE GCKR, GCK, SLC5A1 KMT2A 2958/4885TDP1 4156/4885CA12 3237/4885
US-20120022075-A1 NOVEL PHENYLPYRROLE DERIVATIVE GCKR, GCK, SLC5A1 KMT2A 2958/4885TDP1 4156/4885CA12 3237/4885
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA KMT2A 1656/4885TDP1 4159/4885CA12 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.